The LOGiC study (Lapatinib Optimization Study in HER2 Positive Gastric Cancer), a phase III global study, designed to evaluate clinical endpoints and safety of chemotherapy plus lapatinib, has reached its accrual goal and is ongoing for follow up. Here, ERBB2 is linked to gastric cancer.